H2 tag- SEO Purpose
Better Night time Acid Suppression; Better Day-to-Day Acid Variability Maintenance; GERD: Gastroesophageal reflux disease; H+, K+-ATPase: Hydrogen potassium adenosine triphosphatase; PPI: Proton pump inhibitor, VONOprazan
Although PPIs have been used as a first-line treatment for more than a quarter-century, several issues have emerged that highlightthe need for improvement:1
Delayed Onset of Action: Two-thirds of GERD patients experience insufficient symptom relief after the first PPI dose due to the drug's slow onset, and half still have symptoms after 3 days of treatment.
Genetic Variability: The efficacy of PPIs is affected by cytochrome P450 (CYP) 2C19 polymorphism.
Suboptimal Nighttime Efficacy: PPIs often do not provide adequate relief of symptoms at night.
Stability Issues: PPIs require an acidic environment for activation but are unstable in acidic conditions, necessitating enteric coating.
VONOprazan to the rescue!
VONOprazan achieves maximal and steady-state acid inhibition more effectively after the first dose than conventional PPIs.
It elevates night-time pH to above 4 on the first day. Sustained daily use maintains this pH level, preventing the activation of pepsin produced by chief cells.
Therefore, VONOprazan is a strong acid blocker that has rapid, stable, and long-lasting effects and these effects are found to be stronger than conventional PPIs.
Vono 20-Always on Duty
Vono, containing Vonoprazan molecule, is a Potassium Competitive Acid Blocker which helps in treatment of Refractory GERD, Erosive Esophagitis, H.Pylori, Gastric & Duodenal Ulcers
